Applicability of PD-L1 tests to tailor triple-negative breast cancer treatment in Brazil

• Principais autores: Kátia Ramos Moreira Leite (Autor), Carlos Henrique Barrios (Autor), Antônio Carlos Buzaid (Autor), Débora Gagliato (Autor), Helenice Gobbi (Autor), Fernando Soares (Autor)
• Formato: Livro
• Publicado em: BMC, 2021-04-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Background Triple-negative breast cancer (TNBC) is a heterogeneous disease that represents 10-20% of breast cancer cases. The prognosis for advanced TNBC is usually poor, with a median overall survival of approximately 18 months or less. Main text New targeted therapies such as anti-PD-L1 a...